Translational Research and Interventional Oncology Research Program

项目006 -翻译研究和介入肿瘤学 研究计划 项目总结/摘要 转化研究和介入肿瘤学研究计划（TR）是一个综合性的 跨学科计划，为临床研究人员和实验室科学家提供机会， 共同应对癌症治疗的快速变化。TR跨越多个学科， 包括精确肿瘤学、临床试验、细胞治疗、免疫肿瘤学和免疫毒性，以及TR 领导人的目标是加强不同领域的重要交叉施肥，以改善肿瘤学实践。 在过去的五年里，TR成员继续领导大型多中心临床试验，并一直保持着 科学生产力随着资金的增加而增加。上一个融资周期的两端都出现了增长 频谱除了强大的生产力方面的出版物和联邦赠款资金。TR立志于 促进和推进实体和血液恶性肿瘤双向转化肿瘤学的各个方面 主要目的是优化患者的治疗效果，满足范德比尔特-英格拉姆医院的需求。 癌症中心（VICC）集水区及以外地区。具体目标是引领发展， 实施改变实践的发现，包括监督创新的临床试验， 在国家和国际舞台上由制造商发起和/或积累。TR的翻译科学家旨在 进行范式转变研究，进一步为下一代临床试验提供信息。的出现 免疫肿瘤学已经确定了一个快速发展的未满足的需求，以解决识别有免疫肿瘤风险的患者， 免疫毒性和标准化管理这些毒性的最佳做法。TR成员资格很好- 定位于在检查点抑制剂、免疫细胞抑制剂和免疫细胞抑制剂的范围内引领免疫毒性领域。 治疗和异基因干细胞移植。有来自七个部门的37名计划成员， 两所学校的同行评审资金总额为550万美元，NCI占47%（260万美元）。在826份出版物中， 16%是方案内，24%是方案间。成员还拥有546份合作出版物 与其他国家癌症研究所指定的癌症中心的研究人员进行了合作。

PROJECT 006 – TRANSLATIONAL RESEARCH AND INTERVENTIONAL ONCOLOGY RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT The Translational Research and Interventional Oncology Research Program (TR) is an integrated transdisciplinary program that provides the opportunity for clinical investigators and laboratory scientists to collaboratively address the rapidly changing landscape of cancer therapy. TR traverses multiple disciplines, including precision oncology, clinical trials, cellular therapy, immuno-oncology and immune-toxicity, and TR leaders aim to enhance the vital cross-fertilization across disparate fields that can improve oncologic practice. Over the past five years, TR members have continued to lead large, multi-center clinical trials and have remained scientifically productive with increased funding. The prior funding cycle has seen growth at both ends of that spectrum in addition to strong productivity in terms of publications and federal grant funding. TR aspires to promote and advance all facets of bi-directional translational oncology in solid and hematological malignancies with the main purpose of optimizing patient outcomes that align with serving the needs of the Vanderbilt-Ingram Cancer Center (VICC) catchment area and beyond. The specific aims are targeted to lead development and implementation of practice-changing discoveries, including the oversight of clinical trials that are innovative, investigator-initiated and/or accrue on national and international stages. The translational scientists in TR aim to perform paradigm-shifting research that further informs the next generation of clinical trials. The advent of immuno-oncology has identified a rapidly evolving unmet need to address the identification of patients at risk of immune-toxicity and to standardize best practices for management of those toxicities. TR membership is well- positioned to lead the field of immune-toxicity across the spectrum of checkpoint inhibitors, immune-cellular therapy and allogeneic stem cell transplantations. There are 37 program members from seven departments and two schools with $5.5M in total peer-reviewed funding and NCI making up 47% ($2.6M). Out of 826 publications, 16% are intra-programmatic and 24% are inter-programmatic. Members also have 546 collaborative publications with investigators at other NCI-designated cancer centers.